Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.

GUIDANCE:

Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14